- CEO Seth Lederman makes the case for Tonix Pharmaceuticals (TNXP +29.1%) at the LD Micro VI conference in Los Angeles, though his presentation doesn't appear to contain any new information.
- Webcast and presentation slides
- Results from the pivotal Phase 2b/3 trial of TNX-102 SL for fibromyalgia are expected in 2014 H2, and the Phase 2a trial of the drug for treating PTSD is expected to begin in 2014 Q2.
- Earlier this week: SA Pro's Joe Springer on the opportunity in Tonix.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs